+

MX2024005996A - Inhibidor de kif18a. - Google Patents

Inhibidor de kif18a.

Info

Publication number
MX2024005996A
MX2024005996A MX2024005996A MX2024005996A MX2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A MX 2024005996 A MX2024005996 A MX 2024005996A
Authority
MX
Mexico
Prior art keywords
kif18a
inhibitor
compound
general formula
present
Prior art date
Application number
MX2024005996A
Other languages
English (en)
Inventor
Yuli Xie
Lihui Qian
Yingming Wu
Original Assignee
Wigen Biomedicine Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Tech Shanghai Co Ltd filed Critical Wigen Biomedicine Tech Shanghai Co Ltd
Publication of MX2024005996A publication Critical patent/MX2024005996A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe un inhibidor de KIF18A. Específicamente, la presente invención se refiere a un compuesto de fórmula general (1), un método para prepararlo y el uso del compuesto de fórmula general (1) o un isómero, una forma cristalina, una sal farmacéuticamente aceptable, un hidrato o un solvato del mismo como un inhibidor de KIF18A en la preparación de un medicamento antitumoral. (ver Fórmula).
MX2024005996A 2021-11-19 2022-11-18 Inhibidor de kif18a. MX2024005996A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111399876 2021-11-19
CN202210225663 2022-03-09
CN202210667619 2022-06-13
PCT/CN2022/132954 WO2023088441A1 (zh) 2021-11-19 2022-11-18 Kif18a抑制剂

Publications (1)

Publication Number Publication Date
MX2024005996A true MX2024005996A (es) 2024-05-30

Family

ID=86396297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005996A MX2024005996A (es) 2021-11-19 2022-11-18 Inhibidor de kif18a.

Country Status (8)

Country Link
EP (1) EP4434979A1 (es)
JP (1) JP2024542199A (es)
KR (1) KR20240108489A (es)
CN (1) CN118215657A (es)
AU (1) AU2022389558A1 (es)
CA (1) CA3237625A1 (es)
MX (1) MX2024005996A (es)
WO (1) WO2023088441A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120398830A (zh) 2018-12-20 2025-08-01 美国安进公司 Kif18a抑制剂
WO2023028564A1 (en) 2021-08-26 2023-03-02 Volastra Therapeutics, Inc. Spiro indoline inhibitors of kif18a
CN117466899A (zh) * 2022-07-29 2024-01-30 武汉人福创新药物研发中心有限公司 Kif18a抑制剂及用途
KR20250078442A (ko) 2022-08-18 2025-06-02 액센트 테라퓨틱스, 인크. Kif18a 억제제 및 이의 용도
WO2024083208A1 (zh) * 2022-10-21 2024-04-25 杭州邦顺制药有限公司 Kif18a蛋白抑制剂
WO2024114730A1 (zh) * 2022-11-30 2024-06-06 微境生物医药科技(上海)有限公司 一种用于癌症治疗的药物组合物
EP4628486A1 (en) * 2022-12-02 2025-10-08 Shenzhen Zhongge Biological Technology Co., Ltd. Amide or urea compound
CN120569373A (zh) * 2023-01-05 2025-08-29 浙江海正药业股份有限公司 芳香酰胺类衍生物及其制备方法和医药上的用途
WO2024244972A1 (zh) * 2023-05-30 2024-12-05 浙江海正药业股份有限公司 芳香酰胺类衍生物及其制备方法和用途
WO2025021003A1 (zh) * 2023-07-21 2025-01-30 浙江海正药业股份有限公司 芳香酰胺类衍生物及其制备方法和用途
WO2025026392A1 (zh) * 2023-08-02 2025-02-06 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用
WO2025036479A1 (zh) * 2023-08-16 2025-02-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用
WO2025190888A1 (en) * 2024-03-12 2025-09-18 F. Hoffmann-La Roche Ag Macrocyclic kif18a inhibitors and their use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120398830A (zh) 2018-12-20 2025-08-01 美国安进公司 Kif18a抑制剂
MA54546A (fr) * 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019403488B2 (en) * 2018-12-20 2025-07-24 Amgen Inc. KIF18A inhibitors
WO2020132653A1 (en) * 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
CN114401953A (zh) * 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
EP4007638A1 (en) * 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
US20220289724A1 (en) * 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
KR20230011932A (ko) * 2020-04-14 2023-01-25 암젠 인크 신생물 질환의 치료를 위한 kif18a 저해제

Also Published As

Publication number Publication date
KR20240108489A (ko) 2024-07-09
EP4434979A1 (en) 2024-09-25
JP2024542199A (ja) 2024-11-13
CN118215657A (zh) 2024-06-18
WO2023088441A1 (zh) 2023-05-25
AU2022389558A1 (en) 2024-05-23
CA3237625A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
MX2024005996A (es) Inhibidor de kif18a.
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
ECSP21000990A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
DOP2019000201A (es) Compuestos inhibidores del vih
ECSP19036765A (es) PROCESO PARA LA PREPARACION DE PIRAZOLO[1,5-a]PIRIMIDINAS Y SALES DE ESTAS
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX2019008698A (es) Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY37028A (es) Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds
MX354175B (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria.
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
AR062393A1 (es) Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载